Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

Trethera Corporation initiates a clinical trial for TRE-515, exploring its potential in oncology and autoimmune diseases ...

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...

An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's ...